Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 72

1.

Calprotectin in Daily Practice: Where Do We Stand in 2017?

D'Angelo F, Felley C, Frossard JL.

Digestion. 2017;95(4):293-301. doi: 10.1159/000476062. Epub 2017 May 17. Review.

2.

The course of inflammatory bowel disease during pregnancy and postpartum: a prospective European ECCO-EpiCom Study of 209 pregnant women.

Pedersen N, Bortoli A, Duricova D, D Inca R, Panelli MR, Gisbert JP, Zoli G, López-Sanromán A, Castiglione F, Riegler G, Annese V, Gionchetti P, Prada A, Pont ED, Timmer A, Felley C, Shuhaibar M, Tsianos EV, Dejaco C, Baert FJ, Jess T, Lebech M, Hommes DW, Munkholm P; European Crohn-Colitis Organisation-ECCO-Study Group of Epidemiology Committee-EpiCom.

Aliment Pharmacol Ther. 2013 Sep;38(5):501-12. doi: 10.1111/apt.12412. Epub 2013 Jul 15.

3.

When do we dare to stop biological or immunomodulatory therapy for Crohn's disease? Results of a multidisciplinary European expert panel.

Pittet V, Froehlich F, Maillard MH, Mottet C, Gonvers JJ, Felley C, Vader JP, Burnand B, Michetti P, Schoepfer A; EPACT-II Update Panellists.

J Crohns Colitis. 2013 Nov;7(10):820-6. doi: 10.1016/j.crohns.2013.04.013. Epub 2013 May 9.

PMID:
23664620
4.

Age, smoking and overweight contribute to the development of intestinal metaplasia of the cardia.

Felley C, Bouzourene H, VanMelle MB, Hadengue A, Michetti P, Dorta G, Spahr L, Giostra E, Frossard JL.

World J Gastroenterol. 2012 May 7;18(17):2076-83. doi: 10.3748/wjg.v18.i17.2076.

5.

Efficacy and safety of certolizumab pegol in an unselected crohn's disease population: 26-week data of the FACTS II survey.

Vavricka SR, Schoepfer AM, Bansky G, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Scharl M, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2011 Jul;17(7):1530-9. doi: 10.1002/ibd.21521. Epub 2010 Dec 22.

PMID:
21674709
6.

Systematic evaluation of risk factors for diagnostic delay in inflammatory bowel disease.

Vavricka SR, Spigaglia SM, Rogler G, Pittet V, Michetti P, Felley C, Mottet C, Braegger CP, Rogler D, Straumann A, Bauerfeind P, Fried M, Schoepfer AM; Swiss IBD Cohort Study Group.

Inflamm Bowel Dis. 2012 Mar;18(3):496-505. doi: 10.1002/ibd.21719. Epub 2011 Apr 20.

PMID:
21509908
7.

Appropriate management of special situations in Crohn's disease (upper gastro-intestinal; extra-intestinal manifestations; drug safety during pregnancy and breastfeeding): Results of a multidisciplinary international expert panel-EPACT II.

Mottet C, Vader JP, Felley C, Froehlich F, Gonvers JJ, Juillerat P, Stockbrügger R, Angelucci E, Seibold F, Michetti P, Pittet V; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):257-63. doi: 10.1016/j.crohns.2009.03.008. Epub 2009 May 14.

PMID:
21172284
8.

Appropriate therapy for fistulizing and fibrostenotic Crohn's disease: Results of a multidisciplinary expert panel - EPACT II.

Felley C, Vader JP, Juillerat P, Pittet V, O'Morain C, Panis Y, Vucelic B, Gonvers JJ, Mottet C, Froehlich F, Michetti P; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):250-6. doi: 10.1016/j.crohns.2009.06.001. Epub 2009 Aug 22.

PMID:
21172283
9.

Appropriate maintenance treatment for Crohn's disease: Results of a multidisciplinary international expert panel - EPACT II.

Juillerat P, Vader JP, Felley C, Pittet V, Gonvers JJ, Mottet C, Bemelman WA, Lémann M, Oresland T, Michetti P, Froehlich F; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):241-9. doi: 10.1016/j.crohns.2009.05.002. Epub 2009 Jul 14.

PMID:
21172282
10.

Appropriateness of therapy for active Crohn's disease: Results of a multidisciplinary international expert panel-EPACT II.

Michetti P, Stelle M, Juillerat P, Gassull M, Heil FJ, Stange E, Mottet C, Gonvers JJ, Pittet V, Vader JP, Froehlich F, Felley C; EPACT II Study Group.

J Crohns Colitis. 2009 Dec;3(4):232-40. doi: 10.1016/j.crohns.2009.05.003. Epub 2009 Jul 15.

PMID:
21172281
11.

Recurrent Acute Pancreatitis and Therapy for Ulcerative Colitis.

Frossard JL, Felley C, Michetti P.

Case Rep Gastroenterol. 2010 Sep 4;4(3):304-306.

12.

Infliximab for Crohn's disease in the Swiss IBD Cohort Study: clinical management and appropriateness.

Juillerat P, Pittet V, Vader JP, Burnand B, Gonvers JJ, de Saussure P, Mottet C, Seibold F, Rogler G, Sagmeister M, Felley C, Michetti P, Froehlich F; Swiss IBD Cohort Study Group.

Eur J Gastroenterol Hepatol. 2010 Nov;22(11):1352-7. Erratum in: Eur J Gastroenterol Hepatol. 2011 Mar;23(3):294. Tempia-Caliera, Michela [corrected to Schäppi, Michela].

PMID:
20964261
13.

Appropriateness of therapy for fistulizing Crohn's disease: findings from a national inflammatory bowel disease cohort.

Pittet V, Juillerat P, Michetti P, Vader JP, Burnand B, Rogler G, Beglinger C, Seibold F, Mottet C, Felley C, Gonvers JJ, Froehlich F; Swiss IBD Cohort Study Group.

Aliment Pharmacol Ther. 2010 Oct;32(8):1007-16. doi: 10.1111/j.1365-2036.2010.04434.x. Epub 2010 Aug 18.

14.

Appropriateness of early management of newly diagnosed Crohn's disease in a European population-based cohort.

Juillerat P, Pittet V, Mottet C, Felley C, Gonvers JJ, Vader JP, Burnand B, Froehlich F, Wolters FL, Stockbrügger RW, Michetti P; EC-IBD Group.

Scand J Gastroenterol. 2010 Dec;45(12):1449-56. doi: 10.3109/00365521.2010.505660. Epub 2010 Jul 26.

PMID:
20653489
15.

Acute complications of Crohn's disease: comparison of multidetector-row computed tomographic enterography with magnetic resonance enterography.

Schmidt S, Guibal A, Meuwly JY, Michetti P, Felley C, Meuli R, Schnyder P, Denys A.

Digestion. 2010;82(4):229-38. doi: 10.1159/000288521. Epub 2010 Jun 25.

PMID:
20588038
16.

Efficacy and safety of certolizumab pegol induction therapy in an unselected Crohn's disease population: results of the FACTS survey.

Schoepfer AM, Vavricka SR, Binek J, Felley C, Geyer M, Manz M, Rogler G, de Saussure P, Sauter B, Seibold F, Straumann A, Michetti P; Swiss IBDnet.

Inflamm Bowel Dis. 2010 Jun;16(6):933-8. doi: 10.1002/ibd.21127.

PMID:
20014021
17.

TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide.

Pache I, Rogler G, Felley C.

Swiss Med Wkly. 2009 May 16;139(19-20):278-87. doi: smw-12549. Review.

18.

[Main therapeutic advances in IBD in 2008].

Felley C, Mottet C, Hess J, Maillard MH, Delarive J, Michetti P.

Rev Med Suisse. 2009 Jan 21;5(187):185-6, 188-90, 192-4. French.

PMID:
19271429
19.

Unusual Masses of the Pancreas to Be Aware of.

Genevay M, Dumonceau JM, Berney T, Terraz S, Felley C, Morel P, Frossard JL.

Case Rep Gastroenterol. 2009 Nov 21;3(3):389-394.

20.

[Acute diarrhea: proposal for outpatient management].

de Vallière S, Pasche O, Felley C, Cornuz J.

Rev Med Suisse. 2008 Nov 26;4(181):2586-8, 2590. Review. French.

PMID:
19066147

Supplemental Content

Loading ...
Support Center